BR112017013936A2 - inibidores de bace1 seletivos. - Google Patents
inibidores de bace1 seletivos.Info
- Publication number
- BR112017013936A2 BR112017013936A2 BR112017013936A BR112017013936A BR112017013936A2 BR 112017013936 A2 BR112017013936 A2 BR 112017013936A2 BR 112017013936 A BR112017013936 A BR 112017013936A BR 112017013936 A BR112017013936 A BR 112017013936A BR 112017013936 A2 BR112017013936 A2 BR 112017013936A2
- Authority
- BR
- Brazil
- Prior art keywords
- bace1 inhibitors
- selective bace1
- selective
- inhibitors
- compound
- Prior art date
Links
- 229940125759 BACE1 protease inhibitor Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
Abstract
a presente invenção provê um composto de fórmula ii: ou um seu sal farmaceuticamente aceitável.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562119391P | 2015-02-23 | 2015-02-23 | |
PCT/US2016/018160 WO2016137788A1 (en) | 2015-02-23 | 2016-02-17 | Selective bace1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017013936A2 true BR112017013936A2 (pt) | 2018-01-02 |
Family
ID=55442893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017013936A BR112017013936A2 (pt) | 2015-02-23 | 2016-02-17 | inibidores de bace1 seletivos. |
Country Status (27)
Country | Link |
---|---|
US (1) | US9522923B2 (pt) |
EP (1) | EP3262051B1 (pt) |
JP (1) | JP6111001B1 (pt) |
KR (1) | KR101945139B1 (pt) |
CN (1) | CN107257801B (pt) |
AR (1) | AR103680A1 (pt) |
AU (1) | AU2016223072B2 (pt) |
BR (1) | BR112017013936A2 (pt) |
CA (1) | CA2972098A1 (pt) |
CL (1) | CL2017002090A1 (pt) |
CO (1) | CO2017008382A2 (pt) |
CR (1) | CR20170315A (pt) |
DO (1) | DOP2017000178A (pt) |
EA (1) | EA031546B1 (pt) |
EC (1) | ECSP17054980A (pt) |
GT (1) | GT201700185A (pt) |
IL (1) | IL252969A0 (pt) |
MX (1) | MX367940B (pt) |
NZ (1) | NZ732940A (pt) |
PE (1) | PE20171337A1 (pt) |
PH (1) | PH12017501523A1 (pt) |
SG (1) | SG11201705764SA (pt) |
SI (1) | SI3262051T1 (pt) |
TN (1) | TN2017000355A1 (pt) |
TW (1) | TWI627177B (pt) |
WO (1) | WO2016137788A1 (pt) |
ZA (1) | ZA201704293B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
US9938266B2 (en) | 2015-03-19 | 2018-04-10 | Eli Lilly And Company | Selective BACE1 inhibitors |
AR104241A1 (es) | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
MX2018011784A (es) | 2016-03-31 | 2019-02-13 | Janssen Pharmaceuticals Inc | Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue. |
WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EP3500296A1 (en) * | 2016-08-18 | 2019-06-26 | Eli Lilly and Company | Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
PE20200342A1 (es) | 2017-05-22 | 2020-02-14 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI332005B (en) | 2005-06-14 | 2010-10-21 | Schering Corp | Aspartyl protease inhibitors |
CA2711655C (en) | 2008-01-18 | 2013-03-05 | Eisai R&D Management Co., Ltd. | Condensed aminodihydrothiazine derivative |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
KR20110076965A (ko) | 2008-09-30 | 2011-07-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규한 축합 아미노 디하이드로티아진 유도체 |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
WO2011071057A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
US20120245155A1 (en) | 2009-12-11 | 2012-09-27 | Shionogi & Co., Ltd. | Fused heterocyclic compound having amino group |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101140D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US8598161B2 (en) | 2011-05-24 | 2013-12-03 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
GB201212816D0 (en) * | 2012-07-19 | 2012-09-05 | Eisai Ltd | Novel compounds |
WO2014015125A1 (en) | 2012-07-19 | 2014-01-23 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivative salts and uses thereof |
TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
JO3318B1 (ar) * | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
AR104241A1 (es) * | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
-
2016
- 2016-02-12 AR ARP160100396A patent/AR103680A1/es unknown
- 2016-02-15 TW TW105104352A patent/TWI627177B/zh not_active IP Right Cessation
- 2016-02-17 AU AU2016223072A patent/AU2016223072B2/en not_active Ceased
- 2016-02-17 CA CA2972098A patent/CA2972098A1/en not_active Abandoned
- 2016-02-17 US US15/045,305 patent/US9522923B2/en not_active Expired - Fee Related
- 2016-02-17 NZ NZ732940A patent/NZ732940A/en not_active IP Right Cessation
- 2016-02-17 EA EA201791684A patent/EA031546B1/ru not_active IP Right Cessation
- 2016-02-17 BR BR112017013936A patent/BR112017013936A2/pt not_active Application Discontinuation
- 2016-02-17 CN CN201680011583.5A patent/CN107257801B/zh not_active Expired - Fee Related
- 2016-02-17 MX MX2017010861A patent/MX367940B/es active IP Right Grant
- 2016-02-17 TN TNP/2017/000355A patent/TN2017000355A1/en unknown
- 2016-02-17 SI SI201630428T patent/SI3262051T1/sl unknown
- 2016-02-17 KR KR1020177023007A patent/KR101945139B1/ko active IP Right Grant
- 2016-02-17 JP JP2016558188A patent/JP6111001B1/ja not_active Expired - Fee Related
- 2016-02-17 PE PE2017001256A patent/PE20171337A1/es unknown
- 2016-02-17 SG SG11201705764SA patent/SG11201705764SA/en unknown
- 2016-02-17 WO PCT/US2016/018160 patent/WO2016137788A1/en active Application Filing
- 2016-02-17 CR CR20170315A patent/CR20170315A/es unknown
- 2016-02-17 EP EP16706731.3A patent/EP3262051B1/en active Active
-
2017
- 2017-06-18 IL IL252969A patent/IL252969A0/en unknown
- 2017-06-23 ZA ZA2017/04293A patent/ZA201704293B/en unknown
- 2017-07-31 DO DO2017000178A patent/DOP2017000178A/es unknown
- 2017-08-01 GT GT201700185A patent/GT201700185A/es unknown
- 2017-08-16 CO CONC2017/0008382A patent/CO2017008382A2/es unknown
- 2017-08-16 CL CL2017002090A patent/CL2017002090A1/es unknown
- 2017-08-22 EC ECIEPI201754980A patent/ECSP17054980A/es unknown
- 2017-08-23 PH PH12017501523A patent/PH12017501523A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017013936A2 (pt) | inibidores de bace1 seletivos. | |
EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
TW201613872A (en) | IRAK4 inhibiting agents | |
MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
EA201592183A1 (ru) | Ингибиторы bace | |
DOP2018000042A (es) | Antagonistas del receptor de cgrp | |
EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
CO2019005165A2 (es) | Compuesto de piridona como inhibidor de c-met | |
EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
BR112018012325A2 (pt) | métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída | |
SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
AU2016330503A8 (en) | Therapeutic compounds and methods of use thereof | |
CY1119540T1 (el) | Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt | |
EA201791596A1 (ru) | Пиразоловые соединения | |
UA107885U (uk) | Застосування вінборону для профілактики гастропатії, індукованої ібупрофеном | |
TH168624B (th) | อนุพันธ์กลูโคไพแรโนซิล-ซับสทิทิวเทด อินโดล-ยูเรีย และการใช้สารเหล่านั้น เป็นตัวยับยั้ง sglt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |